| Project/Area Number |
16K19013
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
SATO Teruki 秋田大学, 医学(系)研究科(研究院), 助教 (30733422)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Kuba Keiji 秋田大学, 大学院医学系研究科 分子機能学・代謝機能学講座, 教授 (10451915)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | ELABELA / APJ / 心不全 / 心腎連関 / 心保護効果 / レニンアンジオテンシン系 / 心肥大 |
|---|
| Outline of Final Research Achievements |
In this study, we investigated the functional role of a novel ligand for APJ receptor, ELABELA, in controlling heart function. ELABELA has been identified as a second ligand for APJ receptor, while Apelin has been thought to be only ligand for APJ receptor. We showed that ELABELA-APJ axis protects from pressure overload-induced heart failure possibly via suppression of ACE expression. In addition, we analyzed the role of ELA in the renal collecting duct.
|
